Key facts
- This page summarizes Liwei Lorraine Lin's Form 4 filing for NovaBridge Biosciences (NBP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jul 2026, 17:00.
Liwei Lorraine Lin - 08 Jul 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)
- Reporting relationship
- General Counsel
- Issuer ticker
- NBP
- Reported as of
- 08 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jul 2026, 17:00:11 UTC
- Prior SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kyler Lei as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Liwei Lorraine Lin filed Form 4 for NovaBridge Biosciences (NBP) on 10 Jul 2026.
Change
- Previous filing in this sequence was filed on 18 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002114156
Primary reporting owner
Lin Liwei Lorraine
- Relationship
- General Counsel
- Address
- C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
- Signature
- /s/ Kyler Lei as attorney-in-fact
- Signature date
- 10 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBP
transaction
Derivative
2025 Employee Share Option (right to buy)
Award
- Transaction value
- Shares
- +254,780
- Change %
- Price
- $0.000000*
- Shares after
- 254,780
- Date
- 08 Jul 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 254,780
- Exercise price
- $1.93
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").
Footnote F2
The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter.
Footnote F3
The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.